Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
CLEARI
Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
Status
Status :
Completed
Type of study
Phase III
Min. Age
2
Years old
Max. Age
11
Years old
Gender
All
Therapeutic area :
Respiratory
Disease :
Respiratory infection
Study medication :
Ribomunyl
Phase :
Phase III
Start Date :
02 September 2013
End date :
17 October 2016
Study ID :
J0022X ST 302
EudraCT/CTIS number :
2013-001760-31
CT.gov Number :
NCT01948856
Send by email